Search





Search





Markets
/
Stocks
/
cccc
/

C4 Therapeutics Inc

CCCC

Add to Watchlist

3.480USD

-0.180-4.92%

Close 07-31 16:00（ET）Quotes delayed by 15 min

384.77MMarket Cap

LossP/E TTM

C4 Therapeutics Inc

3.480

-0.180-4.92%

Financial Summary Income Statement Balance Sheet Cash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial Summary Income Statement Balance Sheet Cash Flow Statement

CCCC Cash Flow Statement

You can access the annual and quarterly cash flow statements of C4 Therapeutics Inc to evaluate its financial soundness and stability.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021Q4

FY2021Q3

FY2021Q2

FY2021Q1

FY2020Q4

FY2020Q3

Operating cash flows (indirect method)

Cash flow from continuing operating activities

10.04%-29.94M

-23.49%-22.14M

-29.31%-31.21M

-142.40%-12.06M

-83.71%-33.28M

25.31%-17.93M

21.41%-24.13M

73.82%-4.97M

45.30%-18.12M

17.57%-24.01M

-9.59%-30.71M

14.41%-19.00M

-24.55%-33.13M

-13.47%-29.13M

-52.63%-28.02M

-23.29%-22.20M

-6.67%-26.60M

-19.18%-25.67M

-27.52%-18.36M

---18.00M

---24.93M

---21.54M

---14.40M

Net income from continuing operations

4.53%-25.13M

40.75%-20.49M

-30.41%-32.17M

-46.87%-26.02M

7.19%-26.32M

0.52%-34.57M

8.77%-24.67M

50.68%-17.72M

18.46%-28.36M

6.54%-34.75M

15.40%-27.04M

-31.04%-35.92M

-9.99%-34.78M

-137.48%-37.19M

-29.47%-31.96M

-21.40%-27.41M

-50.78%-31.62M

28.16%-15.66M

-13.04%-24.68M

---22.58M

---20.97M

---21.80M

---21.84M

Operating gains losses

-11.40%404.00K

-10.83%428.00K

2432.35%11.19M

37.28%615.00K

1.79%456.00K

11.63%480.00K

-1.12%442.00K

-2.18%448.00K

-17.80%448.00K

-17.47%430.00K

7.71%447.00K

5.29%458.00K

78.69%545.00K

61.30%521.00K

25.76%415.00K

12.11%435.00K

-32.37%305.00K

-11.51%323.00K

-21.43%330.00K

--388.00K

--451.00K

--365.00K

--420.00K

Other non-cash items

-57.17%382.00K

16.70%587.00K

362.69%1.20M

2364.44%1.11M

300.00%892.00K

-9.04%503.00K

-77.95%260.00K

-93.25%45.00K

-79.33%223.00K

-56.70%553.00K

-31.45%1.18M

-71.03%667.00K

-46.69%1.08M

-12.59%1.28M

60.60%1.72M

162.49%2.30M

235.10%2.02M

226.85%1.46M

105.17%1.07M

--877.00K

--604.00K

--447.00K

--522.00K

Change in working capital

40.14%-8.27M

-190.00%-6.68M

-78.11%-16.03M

23.50%7.25M

-511.62%-13.82M

118.13%7.42M

33.31%-9.00M

-37.41%5.87M

153.97%3.36M

615.61%3.40M

-220.72%-13.50M

265.40%9.38M

0.37%-6.22M

96.36%-660.00K

-262.13%-4.21M

-195.98%-5.67M

29.56%-6.24M

-212.39%-18.15M

-139.79%-1.16M

---1.92M

---8.86M

---5.81M

--2.92M

-Change in receivables

90.22%-482.00K

-42.80%4.14M

52.68%-4.34M

-53.13%5.83M

-173.82%-4.93M

164.06%7.24M

-1837.50%-9.17M

2586.20%12.43M

-290.37%-1.80M

-75433.33%-11.30M

137.84%528.00K

-893.65%-500.00K

-76.04%945.00K

101.72%15.00K

-83.77%222.00K

102.46%63.00K

376.33%3.94M

-153.94%-871.00K

-68.94%1.37M

---2.56M

--828.00K

---343.00K

--4.41M

-Change in prepaid expenses

-64.22%122.00K

-7964.29%-2.26M

-170.10%-572.00K

914.57%3.63M

107.30%341.00K

-102.12%-28.00K

217.92%816.00K

-127.91%-446.00K

-1037.75%-4.67M

671.35%1.32M

54.02%-692.00K

13.09%1.60M

61.17%498.00K

103.42%171.00K

-2567.21%-1.50M

223.84%1.41M

872.50%309.00K

-242.43%-5.00M

141.50%61.00K

---1.14M

---40.00K

---1.46M

---147.00K

-Change in payables and accrued expense

----

135.81%627.00K

12.18%-6.73M

-23.29%3.98M

669.17%4.17M

-426.07%-1.75M

-108.80%-7.66M

92.50%5.18M

-129.58%-733.00K

-85.40%537.00K

2.55%-3.67M

26.09%2.69M

28.66%2.48M

-7.61%3.68M

-2.73%-3.77M

456.43%2.13M

-49.10%1.93M

--3.98M

---3.67M

---599.00K

--3.78M

-Change in other current liabilities

-492.93%-2.77M

-285.99%-8.68M

-65.47%-6.76M

-24.93%-2.93M

-102.52%-467.00K

-124.34%-2.25M

61.38%-4.08M

-129.95%-2.35M

779.71%18.56M

769.49%9.24M

-100.68%-10.57M

177.40%7.84M

53.57%-2.73M

90.84%-1.38M

-44.25%-5.27M

-294.08%-10.12M

-56.06%-5.88M

-298.68%-15.06M

15.17%-3.65M

---2.57M

---3.77M

---3.78M

---4.30M

Cash from non-recurring investing activities

Cash from operating activities

10.04%-29.94M

-23.49%-22.14M

-29.31%-31.21M

-142.40%-12.06M

-83.71%-33.28M

25.31%-17.93M

21.41%-24.13M

73.82%-4.97M

45.30%-18.12M

17.57%-24.01M

-9.59%-30.71M

14.41%-19.00M

-24.55%-33.13M

-13.47%-29.13M

-52.63%-28.02M

-23.29%-22.20M

-6.67%-26.60M

-19.18%-25.67M

-27.52%-18.36M

---18.00M

---24.93M

---21.54M

---14.40M

Investing cash flow

Net cash from continuing investing activities

--64.00K

375.00%11.00K

3261.54%411.00K

-6.09%185.00K

----

-102.55%-4.00K

-102.17%-13.00K

-45.58%197.00K

-100.00%0.00

-89.46%157.00K

-81.85%600.00K

-31.57%362.00K

242.44%589.00K

1266.97%1.49M

--3.31M

-29.18%529.00K

-59.14%172.00K

-62.54%109.00K

-100.00%0.00

--747.00K

--421.00K

--291.00K

--284.00K

Capital expenditures

--64.00K

--11.00K

--411.00K

-6.09%185.00K

----

-45.58%197.00K

-100.00%0.00

-89.46%157.00K

-81.85%600.00K

-31.57%362.00K

242.44%589.00K

1266.97%1.49M

--3.31M

-29.18%529.00K

-59.14%172.00K

-62.54%109.00K

-100.00%0.00

--747.00K

--421.00K

--291.00K

--284.00K

Net cash flow from disposal of fixed assets

--64.00K

375.00%11.00K

3261.54%411.00K

-6.09%185.00K

----

-102.55%-4.00K

-102.17%-13.00K

-45.58%197.00K

-100.00%0.00

-89.46%157.00K

-81.85%600.00K

-31.57%362.00K

242.44%589.00K

1266.97%1.49M

--3.31M

-29.18%529.00K

-59.14%172.00K

-62.54%109.00K

-100.00%0.00

--747.00K

--421.00K

--291.00K

--284.00K

Net cash flow from investment products

-44.32%16.22M

-690.68%-80.72M

2918.12%4.50M

439.79%39.11M

154.55%29.13M

-57.43%13.67M

-99.74%149.00K

-174.20%-11.51M

-198.66%-53.40M

197.96%32.10M

151.20%58.33M

-54.05%15.51M

1512.32%54.12M

118.17%10.77M

123.07%23.22M

1.74%33.76M

93.75%-3.83M

-9.97%-59.30M

-214.10%-100.63M

--33.18M

---61.31M

---53.93M

---32.04M

Net cash flow from other investing activities

--0.00

----

---1.00K

----

Cash from non-current investing activities

Net cash flow from investing activities

-44.54%16.15M

-690.59%-80.73M

2422.22%4.09M

432.49%38.92M

154.55%29.13M

-57.21%13.67M

-99.72%162.00K

-177.28%-11.71M

-199.75%-53.40M

244.09%31.95M

189.87%57.73M

-54.41%15.15M

1436.94%53.53M

115.63%9.28M

119.79%19.91M

2.45%33.23M

93.51%-4.00M

-9.58%-59.41M

-211.34%-100.63M

--32.43M

---61.73M

---54.22M

---32.32M

Financing cash flow

Cash flow from continuous financing activities

1104.35%462.00K

105857.14%118.67M

-26.01%7.77M

-100.00%0.00

-100.13%-46.00K

-99.81%112.00K

197.70%10.51M

118.10%135.00K

5155.99%34.58M

122606.38%57.67M

-3078.67%-10.75M

-388.03%-746.00K

-242.50%-684.00K

-89.91%47.00K

-38.18%361.00K

-99.85%259.00K

417.88%480.00K

-99.76%466.00K

-76.63%584.00K

--170.50M

---151.00K

--194.05M

--2.50M

Net cash flow from debt Issuance/repayment

----

--0.00

100.00%0.00

--0.00

---11.00M

---750.00K

----

--0.00

----

--0.00

Net cash flow from common stock issuance/repurchase

-29.03%-200.00K

--1.80M

-26.42%7.50M

--0.00

-100.46%-155.00K

-100.00%0.00

63825.00%10.20M

--0.00

36248.94%33.98M

--57.67M

---16.00K

--0.00

---94.00K

--0.00

-100.00%0.00

100.00%0.00

-100.00%0.00

100.00%0.00

--28.00K

---314.00K

--193.15M

---2.00M

Net cash flow from preferred stock issuance/repurchase

----

--0.00

-100.00%0.00

--0.00

----

--0.00

--4.50M

Proceeds from stock option exercised by employees

--605.00K

-100.00%0.00

723.08%107.00K

-100.00%0.00

--111.00K

--13.00K

6650.00%135.00K

826.79%519.00K

-100.00%0.00

-99.23%2.00K

-78.46%56.00K

-93.75%47.00K

-75.83%211.00K

-51.95%259.00K

56.63%260.00K

-15.22%752.00K

--873.00K

--539.00K

--166.00K

--887.00K

--0.00

Proceeds from issuance of warrants

--1.00K

----

Net cash flow from other financing activities

-48.62%56.00K

11687000.00%116.87M

-44.78%164.00K

--0.00

29.76%109.00K

200.00%1.00K

12.93%297.00K

-100.00%0.00

-19.23%84.00K

---1.00K

75.33%263.00K

--2.00K

-52.73%104.00K

100.00%0.00

151.90%150.00K

-100.00%0.00

7433.33%220.00K

-1887.50%-286.00K

---289.00K

--169.93M

---3.00K

--16.00K

----

Net cash from non-recurrent financing activities

Net cash from financing activities

1104.35%462.00K

105857.14%118.67M

-26.01%7.77M

-100.00%0.00

-100.13%-46.00K

-99.81%112.00K

197.70%10.51M

118.10%135.00K

5155.99%34.58M

122606.38%57.67M

-3078.67%-10.75M

-388.03%-746.00K

-242.50%-684.00K

-89.91%47.00K

-38.18%361.00K

-99.85%259.00K

417.88%480.00K

-99.76%466.00K

-76.63%584.00K

--170.50M

---151.00K

--194.05M

--2.50M

Net cash flow

Beginning cash balance

32.41%78.05M

-1.33%62.25M

6.59%81.60M

-41.21%54.74M

-54.67%58.94M

-2.07%63.09M

58.96%76.56M

76.48%93.10M

293.65%130.03M

21.95%64.42M

-20.50%48.16M

7.05%52.76M

-58.40%33.03M

-67.79%52.83M

-78.55%60.58M

-49.45%49.28M

-56.92%79.40M

148.48%164.02M

156.21%282.42M

--97.49M

--184.30M

--66.01M

--110.23M

Current period cash flow changes

-216.90%-13.33M

480.58%15.79M

-43.69%-19.35M

262.37%26.86M

88.61%-4.21M

-106.33%-4.15M

-182.79%-13.46M

-260.07%-16.55M

-287.26%-36.93M

431.40%65.61M

310.01%16.27M

-140.69%-4.59M

165.48%19.72M

76.60%-19.80M

93.46%-7.75M

-93.89%11.29M

65.31%-30.12M

-171.53%-84.62M

-167.77%-118.40M

--184.93M

---86.81M

--118.29M

---44.22M

Ending cash balance

18.23%64.72M

32.41%78.05M

-1.33%62.25M

6.59%81.60M

-41.21%54.74M

-54.67%58.94M

-2.07%63.09M

58.96%76.56M

76.48%93.10M

293.65%130.03M

21.95%64.42M

-20.50%48.16M

7.05%52.76M

-58.40%33.03M

-67.79%52.83M

-78.55%60.58M

-49.45%49.28M

-56.92%79.40M

148.48%164.02M

--282.42M

--97.49M

--184.30M

--66.01M

Free cash flow

9.85%-30.01M

-23.56%-22.16M

-31.02%-31.62M

-136.74%-12.24M

-83.71%-33.28M

25.80%-17.93M

22.92%-24.13M

73.29%-5.17M

46.26%-18.12M

21.07%-24.17M

0.06%-31.31M

14.81%-19.36M

-25.95%-33.71M

-18.77%-30.62M

-70.63%-31.32M

-21.20%-22.72M

-5.57%-26.77M

-18.09%-25.78M

-25.05%-18.36M

---18.75M

---25.36M

---21.83M

---14.68M

Currency unit

--USD

Audit opinions

----

FAQs

What is operating cash flow?



Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did C4 Therapeutics Inc Generate?



C4 Therapeutics Inc generated -98.69M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did C4 Therapeutics Inc's Operating Cash Flow Change Year Over Year?



C4 Therapeutics Inc's operating cash flow increased by -51.47% year over year.

What is investing cash flow?



Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does C4 Therapeutics Inc Spend on Capital Expenditures?



C4 Therapeutics Inc spent 607.00K on capital expenditures in the most recent quarter。

What is financing cash flow?



Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has C4 Therapeutics Inc's Financing Cash Flow Changed?



C4 Therapeutics Inc used 126.40M in financing activities in the latest quarter.

What is free cash flow and why does it matter for CCCC?



Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was C4 Therapeutics Inc’s free cash flow in the latest quarter?



Free cash flow was -99.30M reflecting a -51.98% change from the previous year.